• Viral RIPK3 Degradation Shapes Orthopoxvirus Inflammation

  2026-09-24

  Liu and colleagues identified vIRD, an orthopoxvirus factor that engages host SCF machinery to promote RIPK3 ubiquitination and proteasomal degradation, suppressing necroptosis. Viral genetics and mouse studies connect this mechanism to orthopoxvirus replication, inflammation, and disease, while suggesting a testable—but not yet demonstrated—link to NEDD8-dependent cullin activity.

• gE Tail Mutations Improve VZV mRNA Vaccine Responses

  2026-09-24

  Cao and colleagues compared mRNA vaccines encoding full-length varicella-zoster virus glycoprotein E, its extracellular domain, or a C-terminal trafficking-motif mutant. The mutant produced the strongest measured antibody and T-cell responses, supporting further evaluation of antigen-tail design while leaving protective efficacy and safety to be established.

• SNORA38B in NSCLC: Tumor Growth and ICB Response

  2026-09-23

  The study links the snoRNA SNORA38B to NSCLC progression through E2F1-associated regulation of GAB2/AKT/mTOR signaling and an immunosuppressive tumor microenvironment. In mouse models, SNORA38B-targeting locked nucleic acids reduced tumor growth and improved response to immune checkpoint blockade, supporting further preclinical evaluation of this pathway.

• Bradykinin B2 Receptors and Ileal Peristalsis

  2026-09-23

  The reference study provided the first direct pharmacological evidence that bradykinin inhibits the peristaltic reflex in guinea pig ileum through bradykinin B2 receptors. Its pressure-threshold assay and antagonist controls offer a useful framework for separating inhibitory and facilitatory modulation of intestinal motor function.

• CH 223191 for AhR Pathway Experiments

  2026-09-22

  Use CH 223191 to separate aryl hydrocarbon receptor signaling from downstream stress responses in dioxin, intestinal repair, and microbiota-linked assays. This workflow combines concentration-aware antagonism, CYP1A1 readouts, and practical controls for reproducible mechanistic studies.

• DdmDE Plasmid Clearance by ssDNA Loop Extrusion

  2026-09-22

  Yang et al. describe how the DdmDE defense system combines DNA-guided target recognition with DdmD-driven, bidirectional DNA unwinding and subsequent ssDNA cleavage. The study reframes plasmid clearance as a dynamic, multistep process in which transient DNA bubbles, kinetic target discrimination, mechanical extrusion, and strand-selective nuclease activity are functionally coupled.

• Live-Dead Cell Staining Kit Workflow

  2026-09-21

  Build a faster, more informative cell viability assay with Calcein-AM and Propidium Iodide dual fluorescence. This practical workflow shows how to adapt the kit for microscopy, flow cytometry, cytotoxicity studies, and mechanistic research inspired by a dry-eye ferroptosis study.

• Canagliflozin Remodels Diabetic Kidney Mitochondria

  2026-09-21

  Trentin-Sonoda and colleagues show that canagliflozin improves mitochondrial network architecture and bioenergetic performance in proximal tubular cells from hypertensive–diabetic mice. The sex-dependent results extend SGLT2 inhibitor research beyond glucose lowering and provide a mechanistic framework for studying renal protection in diabetic kidney disease.

• Deracoxib for Reliable Cell Assays

  2026-09-20

  This scenario-based guide explains how Deracoxib, SKU B1091, can be evaluated in cell viability, apoptosis, inflammation, and combination-treatment workflows. It connects concentration, solvent, assay compatibility, and vendor-selection decisions to published canine-cell data and practical laboratory controls.

• Red Blood Cell Lysis Buffer: Workflow Guide

  2026-09-19

  Build cleaner blood sample preparation workflows for flow cytometry, nucleic acid extraction, and protein analysis with selective erythrocyte removal. This guide connects practical lysis optimization with bone-biology research while clarifying species limitations, assay controls, and troubleshooting decisions.

• SERCA2–CaN–FoxO1–FABP4 Axis in Atherosclerosis

  2026-09-18

  This 2025 study identifies a mechanistic link between SERCA2 dysfunction, calcineurin/FoxO1 signaling, FABP4 induction, and macrophage foam cell formation. Genetic and pharmacological evidence suggests that interrupting this pathway can normalize lipid handling and reduce atherosclerotic lesion development, while also defining important limitations for translation beyond the mouse model.

• Cerulenin Reveals Leucomycin Biosynthesis

  2026-09-18

  The reference study showed that cerulenin specifically blocks leucomycin production in Streptomyces kitasatoensis by interfering with acetate incorporation into the macrolide, while leaving acetate uptake and bulk protein and RNA synthesis largely unaffected. Its results provided functional evidence that the leucomycin aglycone is assembled through a polyketide pathway involving condensation chemistry related to fatty acid biosynthesis.

• Salvianolic Acid B in Pulmonary Fibrosis

  2026-09-17

  Build a mechanism-led pulmonary fibrosis workflow around LH2 expression, collagen remodeling, and EMT/FMT readouts rather than total collagen alone. This guide shows how to formulate Dan Shen Suan B, structure cell-based experiments, and troubleshoot concentration, vehicle, and assay-interference problems.

• Chloramphenicol for Plasmid Selection Workflows

  2026-09-17

  Build more reproducible plasmid selection assays with a defined translation-inhibition mechanism, concentration window, and storage strategy. This guide also shows how to use chloramphenicol-based selection as a controlled molecular biology readout without confusing it with clinical carbapenemase surveillance.

• ARv7 and EPI-001 in Triple-Negative Breast Cancer

  2026-09-16

  A 2025 study links AR and ARv7 expression with adverse outcomes in triple-negative breast cancer and tests Enzalutamide and EPI-001 in MDA-MB-231 cells. Its integration of patient tissue analysis, TCGA-BRCA data, and migration- and marker-based assays supports ARv7 as a prognostic and mechanistic target, while retaining important preclinical limitations.

7957 records 1/531 page Next 12345 下5页 Last page